Please use this identifier to cite or link to this item:
Title: Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit?
Authors: Sturm, Jonathan ;Gilligan, A.K.;Thrift, A.G.;Dewey, H.M.;Macdonell, R.A.;Donnan, G.A.
Issue Date: 2005
Source: Volume 20, Issue 4, pp. 239 - 244
Journal title: Cerebrovascular Diseases
Abstract: BACKGROUND: Although a number of acute stroke interventions are of proven efficacy, there is uncertainty about their community benefits. We aimed to assess this within a defined population. METHODS: Eligibility for tissue plasminogen activator (tPA), aspirin, stroke unit management and neuroprotection were assessed among incident stroke cases within the community-based North East Melbourne Stroke Incidence Study. RESULTS: Among 306,631 people, there were 645 incident strokes managed in hospital. When eligible patients were extrapolated to the Australian population, for every 1,000 cases, 46 (95% CI 17-69) could have been saved from death or dependency with stroke unit management, 6 (95% CI 1-11) by using aspirin, 11 (95% CI 5-17) or 10 (95% CI 3-16) by using tPA at 3 and 6 h, respectively. CONCLUSIONS: Although tPA is the most potent intervention, management in stroke units has the greatest population benefit and should be a priority.
DOI: 10.1159/000087705
ISSN: 1015-9770
Publicaton type: Journal Article
Keywords: Neurology
Appears in Collections:Neurology

Show full item record

Page view(s)

checked on Jan 30, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.